Smith & Nephew talks with J&J on orthopaedics deal fail over CEO role, source says

{
  "signal_id": "4ff95b98-9b16-3bea-d24a-885217f35bdf",
  "signal_type": "news",
  "signal_subtype": "spins_off_company",
  "detected_at": "2026-10-23T11:50:26+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://wincountry.com/2026/10/23/smith-nephew-merger-talks-with-jj-orthopaedics-unit-collapse-over-ceo-role-ft-reports/",
    "title": "Smith & Nephew talks with J&J on orthopaedics deal fail over CEO role, source says - WNWN-FM",
    "excerpt": "By Sabrina Valle NEW YORK, Oct 23 (Reuters) – Smith & Nephew held talks to merge with Johnson & Johnson’s orthopaedics division but the discussions collapsed over who would run the enlarged group, a person familiar with the ​matter told Reuters on Friday. British medical devices firm Smith & Nephew and US ‌group J&J both declined to comment on an earlier Financial Times report which said the merger talks had been at an advanced stage, with both sides aligned on the main financial terms and structure. The talks fell through at the last minute after Smith & Nephew refused to ‌agree ​to its former CEO Namal Nawana leading the merged ⁠business, the FT report said. “The ⁠combination would have created a rich portfolio across knee and hip implants, while filling in musculoskeletal gaps in both parties’ offering,” said John West, global head of analysis at Mergermarket. Smith & Nephew approached J&J earlier this year with ​an offer valuing the US drugmaker’s hip and knee replacement unit at as much as $22 billion, almost double Smith & Nephew’s £9.4 billion ($12.58 billion) market capitalisation, the ⁠FT said. J&J announced plans a year ago to ⁠separate its orthopaedics business into a standalone company named DePuy ​Synthes. The unit, which was reportedly seeking a $20 billion price tag, has drawn private ​equity interest but no deal has materialised. Last week, J&J said it ‌was...",
    "summary": "Johnson & Johnson plans to spin off its orthopaedics division into a standalone company named DePuy Synthes, targeting a separation for mid-2027.",
    "planning": true,
    "image_url": "https://storage.googleapis.com/media.mwcradio.com/mimesis/2026-10/23/2026-10-23T072616Z_2_LYNXMPEM9M0HU_RTROPTP_3_JOHNSON-JOHNSON-RESULTS.JPG",
    "confidence": 0.9,
    "published_at": "2026-10-23T11:50:26Z",
    "effective_date": "2027-06-01",
    "article_sentence": "Last week, J&J said it ‌was leaning towards a spin-off of the unit, with a separation targeted for mid-2027.",
    "related_company_name": "DePuy Synthes",
    "related_company_domain": "depuysynthes.com"
  }
}

curl https://signals.autobound.ai/v1/signals/4ff95b98-9b16-3bea-d24a-885217f35bdf \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'